Clinical trial
Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2
NCT02733159
Study timeline
Study start (actual)2017-01-04Date precision: day
Registry last updated2025-02-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
University of Birminghamlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02733159 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.